Additionally, treatment strategies involving combinations of PD-1 blockade with the IL-33/ST2 signaling pathway, PD-1 blockade with EP4-targeted therapy, and TIGIT or PD-1 antibodies with ataxia telangiectasia and rad3-related protein inhibitor (ATRi)/radiation therapy (RT) have all demonstrated remarkable therapeutic potential [38,72,73]. This evidence concerns the gene PDCD1 and telangiectasis.